Presentation · Nov 2025 · PDF
Presentations & Publications
ATTRv
This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Presentation · Nov 2025 · PDF
Acoramidis-AHA 2025- Variant ACM and First CVH
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- p.V142I (V122I) ACM analysis
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-NT-proBNP-in-ATTRv-CM
Presentation · Sep 2025 · PDF
Acoramidis-HFSA-2025-OLE-ACM-and-CVH-by-Genotype
Presentation · Aug 2025 · PDF
BBIO - Acoramidis TTR- ESC 2025 - Improvement in NT-proBNP
Presentation · May 2025 · PDF
BBIO - Acoramidis TTR - ESC-HF 2025 - Functional Capacity and Quality of Life in Variant ATTR-CM from ATTRibute-CM
Presentation · Apr 2025 · PDF
Acoramidis TTR - ACC 2025 - Improvements in Serum TTR Levels in Variant Population
Presentation · Dec 2024 · PDF